Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt
Letter from Bob Hariri
Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction For Its Investigational Celularity Tendon Wrap (CTW) To Be Regulated As A Device Within U.S. Food and Drug Administration (FDA) Center For Devices and Radiological Health (CDRH)
Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-up and Pipeline Prioritization of Next-Generation Product Candidates
Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia
Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East
Celularity’s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn’s Disease in Phase 1, Phase 1b/2a and Phase 1b Studies
Celularity Appoints Paul Graves as Chief Communications Officer
Celularity Stockholder Letter About Our Work in Osteoarthritis (OA)
Celularity Announces Halal Certification of its Advanced Cellular Therapeutics, Biomaterial Products and Business Model
Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting
VIEW PRESS RELEASES BY YEAR
THE LATEST COMPANY UPDATES & PRESS RELEASES
Celularity, Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified natural killer (NK) cells, genetically-modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt
Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction For Its Investigational Celularity Tendon Wrap (CTW) To Be Regulated As A Device Within U.S. Food and Drug Administration (FDA) Center For Devices and Radiological Health (CDRH)
Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-up and Pipeline Prioritization of Next-Generation Product Candidates
Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia
Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East
Celularity’s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn’s Disease in Phase 1, Phase 1b/2a and Phase 1b Studies
Celularity Appoints Paul Graves as Chief Communications Officer
Celularity Announces Halal Certification of its Advanced Cellular Therapeutics, Biomaterial Products and Business Model
Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting
Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update